PCNSL Clinical Trial
Official title:
Zanubrutinib Combined With Rituximab and Chemotherapy for Newly-Diagnosed Primary Central Nervous System Large B-Cell Lymphoma Patients Intolerant to Haematopoietic Stem Cell Transplantation
This single-center, open, single-arm study aim to evaluate the efficacy and tolerability of a therapy introducing zanubrutinib on the basis of rituximab and methotrexate (MTX) [or temozolomide (TMZ), if intolerant to MTX] in treating patients newly diagnosed with primary CNS large B-cell lymphoma and intolerant to HSCT.
Participants will receive zanubrutinib in addition to first-line therapy consisting of rituximab and either MTX or TMZ. After treatment of 6 cycles with the new regimen, the patients achieving CR or PR would go on to receive zanubrutinib maintenance of 1 year (if tolerable). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05167630 -
Prognosis Factors in Patients With Primary Central Nervous System Lymphoma
|
||
| Recruiting |
NCT04514393 -
Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma
|
Phase 2 | |
| Recruiting |
NCT04481815 -
Rituximab Plus Methotrexate With or Without Lenalidomide in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
|
Phase 2 | |
| Active, not recruiting |
NCT04438044 -
A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSL
|
Phase 2 | |
| Active, not recruiting |
NCT03392714 -
Bendamustine-based Combination Therapy for PCNSL
|
Phase 2 | |
| Not yet recruiting |
NCT05021770 -
Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05782374 -
Real World Data on Ibrutinib Use in PCNSL Rel/Ref
|